Lizza Hendriks
ELCC 2022 - Lizza Hendriks Lizza Hendriks discusses ho ...
Jordi Remon
ELCC 2022 - Jordi Remon Jordi Remon outlines what need ...
Jarushka Naidoo
ELCC 2022 - Jarushka Naidoo Jarushka Naidoo depicts re ...
SCLC: prognostic determinants and new treatment modalities
The global, randomized, open-label, phase III CASPIAN trial was initiated to test the anti-PD-L1 antibody durvalumab with or without the CTLA-4 inhibitor tremelimumab in addition to etoposide-platinum chemotherapy (EP) as first-line treatment in patients with extensive-stage small-cell lung cancer (ES-SCLC).
Oncogene-driven lung cancer: EGFR, METex14, ROS1, RET
The neoadjuvant potential of the third-generation EGFR TKI osimertinib was assessed in the multicenter, single-arm, phase II NEOS study that included patients with resectable, stage II-IIIB N2, EGFR-mutant (ex19del/L858R) adenocarcinoma of the lung. Forty patients received osimertinib 80 mg QD for 6 weeks prior to surgery.
Looking more closely at upcoming and established immunotherapy standards
Adjuvant treatment using immune checkpoint inhibition after complete resection of early-stage lung cancer is being investigated considering the modest survival benefit conferred by platinum-based combination chemotherapy in this setting. IMpower010 was the first phase III immunotherapy study to demonstrate a significant disease-free survival (DFS) improvement in the adjuvant setting after platinum-based chemotherapy. Patients included in this trial had undergone complete resection of stage IB-IIIA NSCLC and subsequently received 1–4 cycles of cisplatin-based chemotherapy.
Preface
The European Lung Cancer Congress (ELCC) that took place virtually on 30th March – 2nd April 2022 effectively disseminated the latest advances in lung and thoracic malignancies and gave 131 speakers from all around the world the chance to present promising new research avenues as well as the opportunity for discussions and new perspectives.
抗血管生成组合在后线中表现优异
正在进行的前瞻性非干预性VARGADO研究在常规临床实践中评估血管激酶抑制剂尼达尼布加多西他赛在一线化疗后晚期肺腺癌患者中的作用。VARGADO在德国的约100个地点进行，包括3个队列。队列A分别在一线和二线条件下接受化疗和尼达尼布加多西他赛；对于队列B，免疫检查点抑制（ICI）构成化疗后的二线治疗，然后接受尼达尼布组合；在队列C中，在一线给予化疗加ICI治疗，并且在二线给予尼达尼布加多西他赛（图1）。
“当需要快速缓解时，化疗必不可少”
在过去几年中，由于引入了诸如靶向药物等新药物和免疫疗法，肺癌患者的治疗得到了极大改善。然而，所有数据都显示这些治疗并不适用于所有患者。因此，我们仍然需要化疗。例如，在多线治疗后发生多重耐药时，化疗对于诱导具有驱动突变患者的全身反应可能必不可少。